OPCH stock sentiment todayOption Care Health Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 72% confidence.
Last updated · cached analysis, refreshes periodically
OPCH
Option Care Health IncA dominant market leader in home infusion facing short-term margin compression and regulatory uncertainty despite strong free cash flow.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for OPCH. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently dominated by the aftermath of the failed Amedisys merger and concerns regarding Medicare reimbursement changes for home infusion. While the company is seen as a 'pure play' on the shift toward lower-cost care settings, investors are wary of slowing organic growth and potential GLP-1 impact on their chronic business lines.
- ·Capital allocation strategy post-Amedisys failure
- ·Impact of the Medicare 75/25 rule expiration
- ·M&A speculation and buyback activity
- ·Shift from hospital to home-based care
Financial
Option Care maintains a robust balance sheet with healthy free cash flow generation and manageable leverage (Debt/EBITDA ~2.0x). Revenue growth remains steady, but EBITDA margins have faced slight pressure due to labor inflation and drug mix shifts.
- ·Forward P/E: ~18.5x (slightly below historical average)
- ·LTM Revenue Growth: ~9-11%
- ·Net Debt to EBITDA: ~2.1x
- ·Free Cash Flow Conversion: Strong (>50% of EBITDA)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Reimbursement rate cuts from CMS/private payers
- ·Labor shortages for specialized nursing staff
- ·Drug supply chain disruptions or pricing volatility
- ·Dependency on high-cost specialty pharmaceuticals
Peer temperature
How direct competitors stack up against OPCH right now.
- COLDCVSCVS Health (Coram)
COLDER — Facing massive headwinds in Medicare Advantage and retail pharmacy segments that outweigh their infusion (Coram) stability.
See full analysis → - HOTELVElevance Health (Carelon)
HOTTER — Offers a more diversified managed care model with superior scale and better protection against specific reimbursement shifts.
See full analysis → - HOTTHCTenet Healthcare
HOTTER — Trading at a more attractive EV/EBITDA multiple while benefiting from a surge in high-margin ambulatory surgery volumes.
See full analysis →
- OPCH+2.2%
- CVS-2.4%
- ELV+4.2%
- THC+1.3%
Analyst price target
Consensus average of 12 analysts · median 30.00
Source: StockAnalysis.com · updated 2026-08-03
AI-generated analysis for informational purposes only. Not financial advice.